The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

dihydrotachysterol     3-[2-[1-(5,6-dimethylhept-3- en-2-yl)-7a...

Synonyms: AG-G-58584, CTK8F9213, AC1L1F3W, 67-96-9, DIHYDROTACHYSTEROL, CRYST, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of dihydrotachysterol


High impact information on dihydrotachysterol

  • Bone deficit in ovariectomized rats. Functional contribution of the marrow stromal cell population and the effect of oral dihydrotachysterol treatment [6].
  • Rats were treated orally for 7 d with dihydrotachysterol, which produced significant hypercalcemia with a 15 +/- 2% increase in plasma calcium concentration [7].
  • Fifteen subjects with XLH receiving standard treatment [1,25(OH)2 D3 or dihydrotachysterol plus phosphate] were evaluated, supplemented with placebo, and reevaluated one yr later [8].
  • In one patient from whom the dihydrotachysterol therapy was withdrawn, both immunoreactive and bioactive PTH concentrations increased [9].
  • Upon the institution of cortisol therapy, while still under the effects of a vitamin D analog dihydrotachysterol (DHT), the patient exhibited severe hypocalcemia and tetany [10].

Chemical compound and disease context of dihydrotachysterol


Biological context of dihydrotachysterol


Anatomical context of dihydrotachysterol


Associations of dihydrotachysterol with other chemical compounds


Gene context of dihydrotachysterol


Analytical, diagnostic and therapeutic context of dihydrotachysterol


  1. Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors. Mangat, H., Peterson, L.N., Burns, K.D. J. Clin. Invest. (1997) [Pubmed]
  2. Persistent hypophosphataemia and osteomalacia in dialysis patients not on oral phosphate-binders: Response to dihydrotachysterol therapy. Ahmed, K.Y., Varghese, Z., Wills, M.R., Meinhard, E., Skinner, R.K., Baillod, R.A., Moorhead, J.F. Lancet (1976) [Pubmed]
  3. 1,25(OH)2D levels in dihydrotachysterol-treated patients: influence on 1,25(OH)2D assays. Taylor, A., Norman, M.E. J. Bone Miner. Res. (1987) [Pubmed]
  4. The effects of calciferol and its metabolites on patients with chronic renal failure. I. Calciferol, dihydrotachysterol, and calcifediol. Voigts, A.L., Felsenfeld, A.J., Llach, F. Arch. Intern. Med. (1983) [Pubmed]
  5. Mechanism of action of calcium antagonists in heart and vascular smooth muscle. Fleckenstein, A., Fleckenstein-Grün, G. Eur. Heart J. (1988) [Pubmed]
  6. Bone deficit in ovariectomized rats. Functional contribution of the marrow stromal cell population and the effect of oral dihydrotachysterol treatment. Tabuchi, C., Simmons, D.J., Fausto, A., Russell, J.E., Binderman, I., Avioli, L.V. J. Clin. Invest. (1986) [Pubmed]
  7. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. Earm, J.H., Christensen, B.M., Frøkiaer, J., Marples, D., Han, J.S., Knepper, M.A., Nielsen, S. J. Am. Soc. Nephrol. (1998) [Pubmed]
  8. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study. Carpenter, T.O., Keller, M., Schwartz, D., Mitnick, M., Smith, C., Ellison, A., Carey, D., Comite, F., Horst, R., Travers, R., Glorieux, F.H., Gundberg, C.M., Poole, A.R., Insogna, K.L. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  9. Dissociation of parathyroid hormone bioactivity and immunoreactivity in pseudohypoparathyroidism type I. de Deuxchaisnes, C.N., Fischer, J.A., Dambacher, M.A., Devogelaer, J.P., Arber, C.E., Zanelli, J.M., Parsons, J.A., Loveridge, N., Bitensky, L., Chayen, J. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  10. Cortisol-dihydrotachysterol antagonism in a patient with hypoparathyroidism and adrenal insufficiency: apparent inhibition of bone resorption. Farrell, P.M., Rikkers, H., Moel, D. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  11. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Fleckenstein, A., Frey, M., Fleckenstein-Grün, G. Eur. Heart J. (1983) [Pubmed]
  12. Comparative efficacy of various vitamin D metabolites in the treatment of various types of hypoparathyroidism. Okano, K., Furukawa, Y., Morii, H., Fujita, T. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  13. A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators. Chan, J.C., McEnery, P.T., Chinchilli, V.M., Abitbol, C.L., Boineau, F.G., Friedman, A.L., Lum, G.M., Roy, S., Ruley, E.J., Strife, C.F. J. Pediatr. (1994) [Pubmed]
  14. Linear growth and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases Study. Abitbol, C.L., Warady, B.A., Massie, M.D., Baluarte, H.J., Fleischman, L.E., Geary, D.F., Kaiser, B.A., McEnery, P.T., Chan, J.C. J. Pediatr. (1990) [Pubmed]
  15. Treatment of renal osteodystrophy in children with dihydrotachysterol and 24,25-dihydroxyvitamin D3. van Diemen-Steenvoorde, R., Donckerwolcke, R.A., Bosch, R., Visser, W.J., Raymakers, J.A., Duursma, S.A. Clin. Nephrol. (1985) [Pubmed]
  16. Calpain-mediated AQP2 proteolysis in inner medullary collecting duct. Puliyanda, D.P., Ward, D.T., Baum, M.A., Hammond, T.G., Harris, H.W. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  17. Differences in the bioavailability of dihydrotachysterol preparations. Koytchev, R., Alken, R.G., Vagaday, M., Kunter, U., Kirkov, V. Eur. J. Clin. Pharmacol. (1994) [Pubmed]
  18. Hypocalcaemic cardiac failure. Brenton, D.P., Gonzales, J., Pollard, A.B. Postgraduate medical journal. (1978) [Pubmed]
  19. Effect of dihydrotachysterol on bone induction in ovariectomized rats. Tabuchi, C., Simmons, D.J., Fausto, A., Binderman, I., Avioli, L.V. Bone and mineral. (1989) [Pubmed]
  20. Hypercalcaemia due to dihydrotachysterol treatment in patients with hypothyroidism after thyroidectomy. Lamberg, B.A., Tikkanen, M.J. British medical journal (Clinical research ed.) (1981) [Pubmed]
  21. Calcium redistribution, calcification and stone formation in the parotid gland during experimental stimulation and hypercalcaemia. Cytochemical and X-ray microanalytical investigations. Westhofen, M., Schäfer, H., Seifert, G. Virchows Archiv. A, Pathological anatomy and histopathology. (1984) [Pubmed]
  22. Defective calcium absorption in the proximal small intestine in chronic renal failure: effect of dihydrotachysterol. Coen, G., Segni, M.D., Stirati, G., Cinotti, G.A. Journal d'urologie et de néphrologie. (1976) [Pubmed]
  23. Hypercalcaemia induced by increased thyroxine substitution in a patient treated with dihydrotachysterol. Hallengren, B., Spjuth, J., Dymling, J.F. Acta Endocrinol. (1984) [Pubmed]
  24. The management of hypoparathyroidism with 1alpha-hydroxyvitamin D3. Heyburn, P.J., Peacock, M. Clin. Endocrinol. (Oxf) (1977) [Pubmed]
  25. A comparative study of cholecalciferol, dihydrotachysterol and alfacalcidol in the treatment of elderly patients with hypocalcaemia. Hamdy, R.C., Coles, J.A., Downey, L.J. Age and ageing. (1987) [Pubmed]
  26. Impact of parathyroid status and Ca and vitamin-D supplementation on bone mass and muscle-bone relationships in 208 Belarussian children after thyroidectomy because of thyroid carcinoma. Schneider, P., Biko, J., Reiners, C., Demidchik, Y.E., Drozd, V.M., Capozza, R.F., Cointry, G.R., Ferretti, J.L. Exp. Clin. Endocrinol. Diabetes (2004) [Pubmed]
  27. Effect of plasma calcium concentration on the metabolic clearance rate of calcitonin in the dog. Fox, J., Heath, H. Horm. Metab. Res. (1984) [Pubmed]
  28. Pseudohypoparathyroidism type IA and II with severe neuropsychic manifestations. Kutílek, S., Kabícek, P., Nedvídková, J., Bayer, M. Turk. J. Pediatr. (2001) [Pubmed]
  29. In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. Qaw, F., Calverley, M.J., Schroeder, N.J., Trafford, D.J., Makin, H.L., Jones, G. J. Biol. Chem. (1993) [Pubmed]
  30. Osteomalacia and celiac disease: response to 25-hydroxyvitamin D. Hepner, G.W., Jowsey, J., Arnaud, C., Gordon, S., Black, J., Roginsky, M., Moo, H.F., Young, J.F. Am. J. Med. (1978) [Pubmed]
  31. Calcium: pacesetting the periodic psychoses. Carman, J.S., Wyatt, R.J. The American journal of psychiatry. (1979) [Pubmed]
  32. Suspected pseudohypoparathyroidism in a domestic ferret. Wilson, G.H., Greene, C.E., Greenacre, C.B. J. Am. Vet. Med. Assoc. (2003) [Pubmed]
WikiGenes - Universities